EGFR and diffuse astrocytoma: Therefore, it is not surprising that the study patient with a non-enhancing tumor (grade II diffuse astrocytoma) did not demonstrate an accumulation of cetuximab-IRDye800, suggesting that decreased permeability may prevent the agent from reaching the tumor regardless of EGFR expression.